---
layout: default
title: Lorazepam
parent: 僅模型預測 (L5)
nav_order: 88
evidence_level: L5
indication_count: 10
---

# Lorazepam
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Using the `txgnn-pipeline` skill to confirm this is a Netherlands (NL) TxGNN report generation task. The skill confirms the workflow. Now generating the evaluation report based on the provided Evidence Pack.

---

# Lorazepam: From Anxiety and Sedation to Trigeminal Nerve Neoplasm

## One-Sentence Summary

Lorazepam is a benzodiazepine historically used for anxiety, sedation, and short-term insomnia management.
The TxGNN model predicts it may be effective for **Trigeminal Nerve Neoplasm**,
with **no clinical trials** and **no publications** currently supporting this direction — this prediction is most likely a knowledge graph false positive and should be treated as a warning signal rather than a genuine repurposing candidate.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Anxiety and sedation (benzodiazepine class; no NL marketing authorisation on record) |
| Predicted New Indication | Trigeminal Nerve Neoplasm |
| TxGNN Prediction Score | 99.87% |
| Evidence Level | L5 |
| NL Market Status | Not marketed |
| Number of Authorisations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the provided dataset. Based on known pharmacological information, Lorazepam is a benzodiazepine — a positive allosteric modulator at the GABA-A receptor — that enhances chloride ion influx to produce sedative, anxiolytic, muscle-relaxant, and anticonvulsant effects. Its clinical history includes short-term management of anxiety disorders, procedural sedation, and seizure control.

There is **no established mechanistic link** between GABA-A receptor modulation and trigeminal nerve neoplasm biology. Lorazepam has no known antitumour, anti-angiogenic, or antiproliferative activity. Trigeminal nerve tumours are space-occupying lesions managed primarily through neurosurgery or radiotherapy; benzodiazepines play no recognised role in their pathophysiology or treatment.

The exceptionally high TxGNN score (0.9987, rank 403) is almost certainly attributable to **knowledge graph noise or feature overfitting**: the broad connectivity between drug nodes and neurological disease nodes in the underlying knowledge graph systematically inflates scores for rare neuro-oncological conditions, generating false positives. This is a recognised limitation of graph-based prediction models and should trigger a graph-quality audit rather than clinical follow-up.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Netherlands Market Information

Lorazepam currently holds **no CBG-MEB marketing authorisations** in the Netherlands and is not registered for any indication in the Dutch market. There are therefore no RVG numbers, SmPC documents, or approved indication texts available from the national register.

> For reference: in other jurisdictions where Lorazepam is authorised, the SmPC and PIL should be consulted for safety information, approved indications, and prescribing conditions.

---

## Safety Considerations

Please refer to the SmPC (Summary of Product Characteristics) for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This is an L5 prediction — TxGNN model output only — with no supporting clinical trials, no published literature, no mechanistic basis, and no plausible pharmacological rationale connecting Lorazepam to trigeminal nerve neoplasm. The high numeric score almost certainly reflects systematic false-positive generation in the knowledge graph rather than a genuine drug-disease signal.

**To proceed, the following is needed:**

- **Graph quality audit**: Examine whether the TxGNN knowledge graph systematically over-connects benzodiazepine nodes to rare neurological disease nodes, and apply score recalibration or edge-weight correction
- **Mechanistic hypothesis generation**: Identify, if any, a biological pathway through which GABA-A modulation could influence trigeminal nerve tumour growth or survival — currently none has been proposed
- **Minimum evidence threshold**: At minimum one peer-reviewed case report or in vitro study documenting any benzodiazepine activity relevant to peripheral nerve neoplasm before any further investment in this candidate is warranted
- **MOA data gap resolution**: Retrieve and integrate the full Lorazepam DrugBank entry (DrugBank ID: DB00186) to support future mechanistic plausibility assessments across all predicted indications
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

